Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Previous Page Next Page

Like ovarian cancer, breast cancer can have genetic defects in HRR pathways, which results in HRD [1]. The most well-known HRR genes affected in breast cancer are BRCA1 and BRCA2. The role of defects in other HRR genes such as RAD51C, RAD51D, ATM, BARD1, PALB2 and BRIP1 is currently being characterised.

Further information on the clinical activity of PARP inhibitors in breast cancer can be found by clicking on each topic below.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings